Chris Lu – CEO, Laekna Therapeutics, China
Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which…
Company info
Founded in December 2016, Laekna Therapeutics is a startup biotech company focusing on innovative drug discovery and development, we are dedicated to developing new targeted therapies to treat cancer and liver diseases.
Laekna has strong expertise in both small molecule and antibody discovery and development. Drs. Chris Lu and Yong Yue, and the rest of the leadership team have extensive R&D and management experience in global pharmaceutical companies, along with an exceptional track record of new drug approval and marketing. Laekna is a company full of energy and innovation. Our talented scientists strive to solve the biggest problems in healthcare and bring breakthrough medicines to patients.
Address: Floor 5, No. 987 Cailun Rd, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, China
Website: http://www.laeknatp.com/
Email: communication@laeknatp.com
Dr. Chris Lu, CEO and cofounder of Laekna Therapeutics, shares Laekna’s ambition to deliver cures and improve the quality of life of patients globally, captured by the word ‘Laekna’, which…
In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft…
Founded by Dr Helen Yang and Dr Peter He, Oricell Therapeutics stands at the forefront of next-generation cell and gene therapy innovation. Built on a comprehensive platform that integrates antibody…
Suzhou’s bioBAY has emerged as one of China’s most dynamic biotechnology clusters, bringing together hundreds of biotech and medtech companies within an ecosystem designed to support the full innovation cycle,…
European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both…
Lyon’s leading biotechs have caught the eye of global pharma in recent years, with two major acquisitions attesting to the quality and sophistication of the ecosystem and laying a path…
Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s…
Biotechnology in Taiwan is no longer a future aspiration, but an industrial system deliberately built for global relevance. In this conversation, the Chairman and CEO of the Development Centre for…
Frank Bedu‑Addo shares his journey from scientist to co‑founder and CEO of PDS Biotechnology. He highlights promising progress across PDS’s oncology pipeline, including strategic decisions that have helped improve antitumor…
Following our conversation with CEO Lance Yuen on CK Life Sciences’ strategic direction, Chief Scientific Officer Melvin Toh now takes us inside the scientific engine driving that vision forward. He…
Developing effective CAR-T therapies for T-cell malignancies remains one of the most technically challenging frontiers in cell therapy. Dr Lin Yang of PersonGen Biotherapeutics discusses the company’s progress with its…
Hong Kong is at a strategic inflection point as it seeks to redefine its role in global life sciences through regulatory credibility, institutional design, and long-term positioning between China and…
Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share…
See our Cookie Privacy Policy Here
